TiumBio Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tiumbio.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects
- Conditions
- Hemophilia aHemophilia BBlood Coagulation Disorders
- Interventions
- Drug: Normal saline
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- TiumBio Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06025552
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
- Conditions
- Solid TumorBiliary Tract CancerHead and Neck Squamous Cell CarcinomaColorectal Cancer
- Interventions
- Drug: TU2218 + KEYTRUDA® (Pembrolizumab)
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- TiumBio Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT05784688
- Locations
- 🇰🇷
CHA University Bundang Medical Center, Seongnam, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- TiumBio Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05204862
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
TUC3PII-01_TU2670 Phase IIa Clinical Study
- Conditions
- Endometriosis
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- TiumBio Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05138562
- Locations
- 🇨🇿
University Hospital Hradec Kralove, Hradec Králové, Hradec Kralove, Czechia
🇨🇿Kestr-gyn s.r.o., Gynekologicka ambulance, Náchod, Nachod, Czechia
🇨🇿OB/GYN, Praha, Praha 1, Czechia
News
Endometriosis Clinical Trial Pipeline Shows Promise with 20+ Therapies in Development
• The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies. • Recent clinical trial activity includes positive Phase II results for Hope Medicine's HMI-115 and TiumBio's Merigolix, alongside Lisata Therapeutics' preclinical research. • Key companies like Kissei Pharmaceutical, Mithra Pharmaceuticals, and Organon are advancing novel treatments, including Linzagolix and Estelle, to address unmet needs. • These emerging therapies aim to improve pain management and overall outcomes for the estimated 190 million women affected by endometriosis worldwide.
Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials
• Several companies are actively developing novel therapies for Hemophilia A and B, with many in various phases of clinical trials, showing promise for improving treatment options. • TiumBio Co., Ltd. has submitted a Clinical Trial Application to initiate a Phase 1b investigation of TU7710, a new recombinant activated factor VII for hemophilia patients with inhibitors. • The FDA approved ALTUVIIIO (efanesoctocog alfa) in February 2023, a factor VIII replacement therapy for adults and children with Hemophilia A, for routine prophylaxis and on-demand treatment. • BioMarin received FDA approval for Roctavian in June 2023, a single-dose gene therapy for severe Hemophilia A, marking a significant advancement in treatment.